| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Minerva Neurosciences Inc (NASDAQ: NERV)
NERV Technical Analysis
4
| As on 9th Jun 2023 NERV STOCK Price closed @ 6.96 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.93 & Strong Buy for SHORT-TERM with Stoploss of 0.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NERVSTOCK Price
| Open | 7.00 | Change | Price | % |
| High | 7.10 | 1 Day | 0.01 | 0.14 |
| Low | 6.79 | 1 Week | 0.99 | 16.58 |
| Close | 6.96 | 1 Month | 4.26 | 157.78 |
| Volume | 89200 | 1 Year | 6.04 | 656.52 |
| 52 Week High 13.43 | 52 Week Low 0.35 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NERV Daily Charts |
NERV Intraday Charts |
Whats New @ Bazaartrend |
NERV Free Analysis |
|
|
NERV Important Levels Intraday
| RESISTANCE | 7.56 |
| RESISTANCE | 7.37 |
| RESISTANCE | 7.25 |
| RESISTANCE | 7.13 |
| SUPPORT | 6.79 |
| SUPPORT | 6.67 |
| SUPPORT | 6.55 |
| SUPPORT | 6.36 |
NERV Forecast May 2024
| 4th UP Forecast | 7.36 |
| 3rd UP Forecast | 7.23 |
| 2nd UP Forecast | 7.15 |
| 1st UP Forecast | 7.07 |
| 1st DOWN Forecast | 6.85 |
| 2nd DOWN Forecast | 6.77 |
| 3rd DOWN Forecast | 6.69 |
| 4th DOWN Forecast | 6.56 |
NERV Weekly Forecast
| 4th UP Forecast | 7.33 |
| 3rd UP Forecast | 7.21 |
| 2nd UP Forecast | 7.14 |
| 1st UP Forecast | 7.06 |
| 1st DOWN Forecast | 6.86 |
| 2nd DOWN Forecast | 6.78 |
| 3rd DOWN Forecast | 6.71 |
| 4th DOWN Forecast | 6.59 |
NERV Forecast2024
| 4th UP Forecast | 35.75 |
| 3rd UP Forecast | 26.52 |
| 2nd UP Forecast | 20.81 |
| 1st UP Forecast | 15.1 |
| 1st DOWN Forecast | -1.18 |
| 2nd DOWN Forecast | -6.89 |
| 3rd DOWN Forecast | -12.6 |
| 4th DOWN Forecast | -21.83 |
Minerva Neurosciences Inc ( NASDAQ USA Symbol : NERV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NERV Business Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Address: 1601 Trapelo Road, Waltham, MA, United States, 02451
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service